It helps to read the posts you're replying to.
It is
It helps to read the posts you're replying to.
It is ridiculous to say that purported possible future dilution is a reason to sell a stock that has 3 drugs with multiple successful clinical trials for several different applications, when the market cap is much less than that of companies who have only one drug which is either not as far along as IPIX's, or, like ARTH, have gotten red-flag FDA letters.
With a market cap of 55 million, IPIX is undervalued by a factor of at least 5, and more logically by a factor of 10 or more -- right now.
Cox pumped the stock when it was priced much higher, and didn't even have a single successful clinical trial. Now that it is much, much further along the approval pathway for multiple drugs, and valued much LOWER, he says sell AT MARKET? Panic selling at market is never good for anyone -- unless someone has a motive for wanting to get people to sell low. Like, for instance, if someone is short the stock and wants to cover. Or wants to build a big position as cheap as possible.
3
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Breaking Down Barriers in Thoracic Oncology Picture a world where financial walls don't block innovation and knowledge sharing in cancer treatment. The International Association for the Study of Lung Cancer (IASLC) is leading the charge here. They've just launched a new initiative offering complimentary full membership to qualified healthcare professionals in low- and...
Continue Reading
Stepping into New Territory with SystImmune Amid the cacophony of biotech whispers and the marketplace hum, SystImmune is trotting out something that might just make the folks in lab coats raise an eyebrow. They’ve got new data for Iza-bren—none of that flashy PR chatter—but it's damn promising if you ask me. At the World Conference on Lung Cancer in Seoul,...
Continue Reading
Call it a seismic shift or call it common sense, but ARTiSTORY's recent haul of accolades makes it clear: they're onto something big in the cultural IP game. Receiving four honors at the 26th International Advertising Institute Awards (IAI Awards), including a Gold for their British Library × CHAGEE collaboration, and jumping into License Global's Top 60, they're staking...
Continue Reading
Evolution of South-South Agricultural Cooperation Let's just say if there's a time to shine a spotlight on the arid lands of our world, it's now. The Global Drylands Congress 2026 in New Delhi put a sharp focus on scaling agricultural innovation across these thirsty regions. With climate change breathing down our necks, talking shop about food security isn't just for show...
Continue Reading
Revolutionizing Pathology with a Visual Search Engine In an era where time is money and precision is paramount, Aignostics is betting big on transforming the pathology landscape. Today, their announcement of PathoSearch, a visual search engine designed for retrieving comparable diagnosed pathology cases, marks a massive leap towards streamlining the diagnostic process....
Continue Reading
Global Investment Winds Shift at CIFIT In the thick of a world that's being turned on its head, you've got big shots from 129 countries and 30 international organizations talking shop at the 26th China International Fair for Investment and Trade (CIFIT) in Xiamen. Take your pick from the 48 of the world's top 50 GDP powerhouses rubbing shoulders there—this ain't your...
Continue Reading
ACE 2: A Thermal Riflescope That Promises More Let’s dive right into the nitty-gritty of Nocpix’s latest move. On September 12, they launched the ACE 2 Series—the next-gen beast of their flagship thermal riflescope lineup. A step up from the original ACE, this series aims to redefine what hunters can expect from a riflescope, introducing three models: ACE 2 S60R,...
Continue Reading
China-Europe Trade Ties Continue to Tighten You ever watch a cargo ship glide into port and think, "There's a piece of the future right there”? Well, that's the scene at Poland’s Gdansk Port, now officially etched into the Silk Road Maritime route. This ain't just a couple of extra boats cutting through choppy waters—it's a great leap forward for a strained global...
Continue Reading
Top 5 Most Recently Viewed Articles
BioVaxys Technology Corp. Announces Private Placement Offering BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) is thrilled to share its plans for a strategic move that aims to elevate its operational capabilities. The company intends to initiate a non-brokered private placement offering, introducing up to 14,285,715 units at a price of CAD$0.07 each. This initiative is...
Continue Reading
Cardiff Oncology Completes Significant Stock Offering Cardiff Oncology, Inc. (Nasdaq: CRDF) has recently made headlines with its successful pricing of an underwritten offering, targeting a remarkable $40 million. This offering consists of 15,384,619 shares of its common stock, priced at $2.60 per share, with all shares being offered by the Company itself. The...
Continue Reading
Sungrow and Globeleq Join Forces on Groundbreaking Energy Project Sungrow, a prominent name in the renewable energy sector, and Globeleq, a trusted independent power producer, have made a significant commitment by signing a term sheet. This partnership focuses on the supply and long-term service for the ambitious 153MW / 612MWh Red Sands Battery Energy Storage System...
Continue Reading
Helios Technologies Launches the Versatile S35 Display Helios Technologies, Inc. (NYSE: HLIO), known for its expertise in highly engineered motion control and electronic controls technology, has recently introduced the S35 display. This new addition showcases a unique blend of advanced technology, rugged durability, and user-friendliness, making it an exceptional...
Continue Reading
Ameriprise Financial Achieves All-Time High Ameriprise Financial Inc (NYSE: AMP) has recently marked an extraordinary achievement with its stock price reaching an all-time high of $524.01. This significant increase not only highlights the company’s performance but also reflects a robust surge in investor confidence, demonstrated by a remarkable 65.08% increase over the...
Continue Reading